These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9623588)

  • 1. Successful use of oral valacyclovir in post-transplant cytomegalovirus infection in renal allograft recipients.
    Himmelmann-Jud B; Wüthrich RP; Weinreich T; Binswanger U
    Nephrol Dial Transplant; 1998 May; 13(5):1326-7. PubMed ID: 9623588
    [No Abstract]   [Full Text] [Related]  

  • 2. The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation.
    Le Meur Y; Mons S; Moesch C; Leroux-Robert C
    Nephrol Dial Transplant; 2000 Mar; 15(3):442. PubMed ID: 10692544
    [No Abstract]   [Full Text] [Related]  

  • 3. Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
    Anglicheau D; Lautrette A; Scieux C; Thervet E; Martinez F; Flamant M; Morinet F; Legendre C
    Transplant Proc; 2002 Nov; 34(7):2826-7. PubMed ID: 12431624
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis of cytomegalovirus infection in renal transplantation.
    Ostermann M; MacPhee I; Chang R
    Nephrol Dial Transplant; 2001 Nov; 16(11):2276-9. PubMed ID: 11682689
    [No Abstract]   [Full Text] [Related]  

  • 5. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.
    Kuypers DR; Vanrenterghem YF
    Nephrol Dial Transplant; 1999 Oct; 14(10):2304-8. PubMed ID: 10528649
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP; Legendre C
    J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
    Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
    J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
    Sund F; Tufveson G; Döhler B; Opelz G; Eriksson BM
    Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
    Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
    Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
    Leruez-Ville M; Ghout I; Bussières L; Stirnemann J; Magny JF; Couderc S; Salomon LJ; Guilleminot T; Aegerter P; Benoist G; Winer N; Picone O; Jacquemard F; Ville Y
    Am J Obstet Gynecol; 2016 Oct; 215(4):462.e1-462.e10. PubMed ID: 27083761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine.
    Cantarovich M; Hiesse C; Lantz O; Fassi-Fihri S; Charpentier B; Fries D
    Transplantation; 1988 Jun; 45(6):1139-41. PubMed ID: 2837848
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.
    Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P
    Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.
    Alain S; Hantz S; Scieux C; Karras A; Mazeron MC; Szelag JC; Imbert BM; Fillet AM; Gouarin S; Mengelle C; De Wilde A; Cogne N; Champier G; Rogez S; Legendre C; Denis F
    J Med Virol; 2004 Aug; 73(4):566-73. PubMed ID: 15221901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
    Reischig T; Kacer M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
    Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
    Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.